Peter Brubaker, PhD, is a Professor and Chair in the Department of Health and Exercise Science at Wake
Forest University in Winston-Salem, North Carolina. He was Director of Cardiac Rehabilitation (now
Healthy Exercise and Lifestyle ProgramS) from 1991-2016. He has been an active member (Fellow) for
25+ years of both the American College of Sports Medicine and the American Association of
Cardiopulmonary Rehabilitation. He has published more than 125 articles/chapters in exercise physiology
or cardiology journals/books and authored the textbook Coronary Artery Disease: Essentials of
Prevention and Rehabilitation Programs. He was the Clinical Section Editor (7th ed.) of the ACSM
Guidelines for Exercise Testing and Prescription and was an Associate Editor for Medicine Science in
Sports and Exercise. He is currently an Associate Editor (Literature Update) for the Journal of
Cardiopulmonary Rehabilitation and Prevention. He has given many national and international keynote
lectures on his research and clinical experiences. For 25+ years his research and clinical work have
focused prevention and management of chronic diseases, particularly heart diseases. Current NIH and
industry-funded research focuses on the effect of exercise and other lifestyle interventions on patients
with heart failure and cancer. He has also been serving as Wake Forest’s Faculty Athletic Representative
to the NCAA and ACC since 2016.
Human Physiology (HES 350/650)
Cardiovascular Disease Management (HES 761)
Clinical Exercise Testing and Prescription (HES 765)
Publications link http://www.ncbi.nlm.nih.gov/pubmed/?term=brubaker+ph
Improving Exercise Capacity with a Tailored Physical Activity Intervention in Lymphoma Patients Undergoing Treatment. NIH R21 CA226960 (PI Hundley Period of Support: 12/01/2018 - 11/30/2023
Objective: This project will test the efficacy of the patient developed exercise physical activity intervention for preventing left ventricular dysfunction and exercise intolerance among patients with lymphoma treated with potentially cardiotoxic chemotherapy.
Transition From Risk Factors to Heart Failure: Prevalence, Pathogenesis, and Phenomics (MESA-ancillary) NIH/NHLBI R01 HL127028 (PI Bertoni)
Period of Support 07/01/15 - 06/30/20
Objective: The goals of this study are to determine the prevalence of early heart failure (HF); elucidate the pathogenesis of early HF; and delineate the key antecedent risk factor combinations associated with the transition from Stage B to Stage C HF among 3,500 older adults attending the year-15 examination of the Multi-Ethnic Study of Atherosclerosis (MESA).
Study of the Effects of Caloric Restriction and Exercise Training II (SECRET II). NIH/NIA R01 AG018915 (PI Kitzman)
Period of Support: 04/01/15-3/31/20
Objective: The primary aim of this study is to conduct a randomized, single-blinded 24-week intervention trial of resistance training (RT) added to caloric restriction (CR) + aerobic exercise training (AT) in 100 overweight/obese (BMI > 28), heart failure with preserved ejection fraction (HFpEF) patients age >60 years.
Cardiovascular Injury, Exercise Intolerance and Fatigue after Adjuvant Chemotherapy for Stage I-III Breast Cancer. NIH/NHLBI R01 (PI Hundley)
Period of Support: 07/01/2015-06/30/2020
Objective: The purpose of this multi-center cohort study is to determine the time course and inter-relationship of abnormalities of cardiovascular function, exercise capacity and fatigue in 1,000 women (and 500 controls) receiving adjuvant chemotherapy for the treatment of Stage I-III breast cancer.